TruthCapital

Business Analysis using core concepts

All information and insights shared for learning . Not to be seen as recommendations. Not SEBI registered.

[TruthCapital @ramesh_vd]

Deep Dive Business Analysis
#Airfloa https://t.co/0MMQ7eKrhp

#sahanasystems #sahanasystem
https://t.co/xMY8mEa857

#orianapower
https://t.co/qpXKwOzdIv

#kalyanicast https://t.co/XSZAKpRLWy

#purpleunited
https://t.co/QxwYNfEB3O

#sunitatools
https://t.co/vUqEO8LdFh

[TruthCapital @ramesh_vd]

@aditya_sh96 Hey ..its written for the effect :) literally it doesnot mean only 1 patent. It implies a broader set of patents for various flow chemistry.

[TruthCapital @ramesh_vd]

#Acutaas #Acutaaschemicals

Acutaas Chemicals — The Flow Chemistry Patent Nobody Is Talking About

Most Indian chemical stocks compete on cost. Acutaas competes on who can even copy them.

One patent. Two industries. Zero substitutes.

Flow chemistry — the moat that serves both Big Pharma and the EV+Semiconductor revolution 🧵👇

What They Do (Business Verticals)
🔵 Pharma Intermediates — 610+ complex molecules for global drug makers
🔵 CDMO — Exclusive chemist for innovators like Fermion (Bayer's cancer drug Darolutamide)
🔵 EV + Semicon — First outside China to make EV electrolyte additives; India's only semiconductor photoresist maker
🔵 Specialty Chemicals — Parabens, salicylic acid, niche consumer materials

The pivot: from generic pharma supplier → deep-tech critical infrastructure.

The Real Moat: Flow Chemistry
Here's what most miss.
Acutaas doesn't just make chemicals. They make them via proprietary continuous flow chemistry processes that competitors simply cannot replicate.

Production-side moat:→ Multi-stage synthesis requires ₹150-200Cr+ capex + 4 years for regulatory clearance → 90%+ of intermediates made fully in-house → USFDA + PMDA approvals are non-transferable — new entrant = full re-audit

Demand-side customer stickiness:→ Their molecules get written INTO client drug patent filings → Switching supplier = $1-3M refiling + 2-3 years of comparative stability testing → Customer retention: 90-95% within CDMO/innovator contracts

Barriers to entry:→ You need the chemistry and the compliance and the regulatory trust — all simultaneously → In FY24, unorganized generic players were wiped out by Chinese dumping. Acutaas survived because they were already unreplicable.

This isn't a patent on a product. It's a patent on the process. You can't reverse-engineer a process you can't observe.

Tweet 4 — Financial Projection + Asymmetric Bet

Numbers back the thesis:

OPM went from 11.2% in FY24 → 42.4% in Q4FY26 as the mix shifted.

The asymmetric bet? Semiconductor photoresists.

Today Acutaas is India's sole manufacturer. Global market = $4.8B → $7.1B by 2030. Their target: 5% global share + 60% domestic share.
The capex is already deployed. The validation cycles are running. If even 1-2 Indian fabs (backed by India Semiconductor Mission) lock them in — the revenue step-change is non-linear.
PAT CAGR guided at ~38% through FY28. At 73x trailing P/E, it's not cheap — but at 40x forward FY28 earnings, it's a different conversation.
FCF is currently negative (-₹12 Cr) — that's the CapEx phase. It flips positive post-FY26. Watch that inflection.

Closing
Acutaas is rare: a company where the supply chain IS the product.
Promoters hold ~40%, zero pledge. Debt-free. ROCE at 31.6%.
The flow chemistry patents don't just protect margins — they determine whether customers can even leave.

[Not investment advice, DYOR]

[TruthCapital @ramesh_vd]

#sigmaadvancedsystems #sigmaadvanced

Sigma Advanced Systems — Could be India's Most Underrated Dual-Engine Defence Play?

What if one company was simultaneously:
🔵 Writing the firmware for India's next-gen missiles 🔴 Machining jet engine parts for Rolls-Royce in the UK
Same balance sheet. Same team.

The Business = two engines running in parallel
Engine 1: Defence Electronics→ Missile & avionics sub-systems → Multi-domain radars & counter-UAS (anti-drone shields) → Naval & submarine ruggedized electronics → CEMILAC + AS 9100 Rev D flight-certified — mandatory for the Indian MoD
Engine 2: Precision Engineering (Aerostructures)→ 5-axis & 8-axis CNC machining of aero-engine housing parts → NADCAP-certified chemical surface treatment — rare globally → Fuelled by the acquisition of UK's Nasmyth Group
Revenue split:
Electronics: sovereign Indian MoD orders
Precision Eng: £300M Rolls-Royce contract (₹3,800 Cr over 7 years)
Q4FY26 revenue: ₹323 Cr (+469% YoY). This is no longer a small-cap experiment.

The Real Moat
This isn't a story about who has the best product. It's about who can even get certified to make it.

Supply-side lock:→ AS 9100 Rev D + NADCAP + CEMILAC + DGQA = 4 separate certifications → Each takes 2–4 years of zero-defect audits → ₹130–190 Cr minimum capex just to set up a competing facility → Certifications are facility-specific and non-transferable

Demand-side lock:→ Sigma's sub-systems are written into OEM master airframe blueprints→ Switching supplier = $2–5M re-validation + 24 months FAA/EASA recertification → Customer retention: >95% on mature platforms

The Nasmyth arbitrage (uncopiable):→ UK front-end for NADCAP finishing + Western OEM relationships → Hyderabad back-end for low-cost 5-axis CNC machining → Sigma takes a Rolls-Royce order. Nasmyth handles the front-end design and NADCAP finishing. Hyderabad handles the bulk CNC carving at 35–40% lower cost. The customer sees a UK-certified supplier. The P&L sees Indian manufacturing costs. → The two nodes are only valuable together — which is precisely what makes the combination hard to replicate. That window has already closed.

The Numbers (Stripped of the Noise)
Before anything else — a flag that separates serious investors from the rest.
FY26 reported PAT is ₹268 Cr. Screener shows EPS of ₹15.21. Both numbers are technically correct and completely misleading. Strip out the ₹262 Cr one-time land and asset sale gains and the actual defence manufacturing business earned ₹16 Cr in core PAT in FY26. Core EPS: ₹2.28. That's the real starting line.

Here's what the core operational business actually looks like:
Revenue is real and scaling — ₹474 Cr in FY26 to a projected ₹938 Cr by FY28. The Rolls-Royce contract alone runs at ₹543 Cr per year. Current installed capacity is ₹600 Cr. A ₹95 Cr capex program in FY27 takes that ceiling to ₹1,250 Cr. The FY28 projection assumes only 75% utilisation — there's 33% upside if execution holds.
Margins today are honest and modest. Core EBITDA is 10.4% in FY26 -- The path to 19% by FY28 is entirely a Nasmyth story. Every machining job that migrates from high-cost UK workshops to Hyderabad flows directly into margin.
By FY28, core PAT reaches ₹108 Cr and fully diluted EPS hits ₹12.67 — on a post-placement share base of 8.50 Cr shares that already prices in the June 2026 preferential allotment.

The working capital discount is real and you need to price it in.
Debtor days sit at 270. Net cash cycle is 310 days. Sigma is essentially pre-financing ~₹350 Cr of working capital for the Ministry of Defence at any given time. The fix is the revenue mix shifting toward Rolls-Royce, which pays on commercial terms. As that happens, debtor days compress to 210 by FY28 and CFO reaches ₹114 Cr. ROIC climbs from 7.1% to 13.4%.

Management & Governance
Promoters hold 71.22%, pledged shares are zero — completely cleared, zero forced liquidation risk, zero overhang — and they chose a ₹460 Cr equity raise over bank debt to fund growth, with India Ratings independently monitoring every rupee of deployment.

The walk-the-talk record is clean: margin pivot promised and delivered, Nasmyth integration promised and delivered, ₹3,800 Cr Rolls-Royce contract signed — founders are fully in, unencumbered, and building with their own skin in the game.

Closing - know the past to forecast the future

This company has a complicated past worth understanding before you size a position.
Megasoft Limited was a Hyderabad-based telecom software company that for years sat dormant on the BSE — negligible revenue, no meaningful business, a shell in all but name. The transformation into a defence engineering company happened through a reverse merger with the unlisted private entity Sigma Advanced Systems, sanctioned by NCLT only in December 2025. The listed vehicle that retail investors are buying today is legally the same entity that was filing near-zero revenue returns as a telecom software company twelve months ago.
Layer on top of that: a ₹262 Cr gain from selling land and assets that inflated FY26 reported profits to ₹268 Cr — numbers that led many investors to build models on ₹15.21 EPS when the actual defence business earned ₹16 Cr in core PAT. And a UK acquisition — Nasmyth Group — executed in November 2025, consolidated for only five months in FY26, carrying its own one-time transaction costs of ₹9.13 Cr, and still in early integration. These are not small footnotes. They are the entire context behind every headline number this company has reported so far.
So the question is whether the overhang from that messy past has been genuinely wiped clean — and the evidence is starting to point that way.
The shell is no longer a shell. The NCLT merger is sanctioned, the name is changed, the promoter structure is consolidated at 71.22% with zero pledged shares. The asset sales that distorted FY26 are one-time and done — they won't repeat, which means FY27 reported numbers will finally reflect only what the factories produce. The ₹460 Cr equity raise retires the debt that the transition period accumulated. And Nasmyth, whatever its integration complexities, just unlocked a £300 Million seven-year contract with Rolls-Royce — one of the most demanding aerospace customers on the planet. You do not win that contract without genuine engineering credibility.
The order book now has a different character entirely. ₹3,800 Cr from Rolls-Royce. ₹208 Cr in artillery shell exports. ₹107 Cr from North American defence customers. A ₹450 Cr electronic warfare contract from the Indian MoD. These are not prototype orders or one-off government allocations — these are series production commitments from customers who spent years validating the supplier before signing.
The past was messy. The transition was opaque to anyone relying on screening platforms. The FY26 numbers require significant stripping before they tell you anything useful. All of that is fair and should be priced into your risk assessment.
But the overhang is structural, not permanent. A dormant shell has been replaced by a live operating entity. A real estate windfall has been replaced by aerospace contracts. And a telecom software footnote in Hyderabad is now a certified Rolls-Royce supply partner with seven years of revenue visibility.
Whether the bright future the order book promises actually converts into cash depends entirely on one thing: Nasmyth workload migrating to Hyderabad fast enough to show up in margins before the market loses patience. Watch the FY27 quarterly filings. When debtor days compress and normalised EBITDA crosses 15%, the transformation story stops being a thesis and starts being a fact.

[Not investment Advice, DYOR]

[TruthCapital @ramesh_vd]

@soubanyoyahooc1 Glad to add value. Keep sharing feedback

[TruthCapital @ramesh_vd]

#kwalitypharma

No blockbuster patent like Venus Remedies. No USFDA exclusivity windows like Senores. Kwality Pharma grows on something quieter — 200+ process dossiers filed across 40 countries, each one locking a global distributor into KPL's factory for the next 3–5 years. Is that enough to double EPS by FY28? Here is the case. 🧵

What it does

KPL manufactures complex sterile injectables across three verticals — general injectables (the cash base), cytotoxic oncology vials via Unit 5 (the growth engine), and hormones and peptides via the newly built Unit 6 (the future inflection, commissioning H2 FY27).

Instead of selling directly, KPL develops a process dossier — years of formulation work, bioequivalence studies, and stability data — and hands it to MNC distributors in Europe and Latin America. The distributor files for local regulatory approval naming KPL's plant as the exclusive manufacturer. KPL earns three ways: a technology transfer fee for the development work it already did, a batch supply margin on every vial shipped, and a profit share from the partner's sales.

The moat — and its honest limits

A patent gives a legal monopoly on a molecule. KPL does not have that — all its molecules are off-patent. The technology transfer fee is not an IP fee either. The partner pays for the ready-made technical package that saves them 2–3 years of work, not for exclusive rights to the molecule.

The real lock-in comes after the dossier is filed. Once the partner's local approval names KPL's specific plant as the manufacturer, replacing KPL means pulling the registration, sourcing a new manufacturer, running fresh bioequivalence studies, and refiling — a 24–36 month penalty per product per market. Time-based switching cost, not legal exclusion. Every new filing adds another layer.

The FY28 numbers — and what drives them

FY26 EPS was ₹64.5. FY28E is projected at ₹136.5 — more than double in two years on a 45% CAGR. At CMP the stock trades at 18.5× FY28E.
FY26A — Sales / EPS / EBITDA₹503 Cr  /  ₹64.5  /  24.1%base

FY28E — Sales / EPS / EBITDA₹830 Cr  /  ₹136.5  /  28.0%+65% sales · EPS ×2.1

Revenue drivers:
↑Unit 6 hormones and peptides — commissions H2 FY27, unlocks ₹150 Cr incremental ceiling at the highest margin in the business; zero in revenue today

↑EU and LatAm corridor deepens — Mexico, Colombia, Brazil filings converting to commercial supply at 2.5× price realisation per unit versus legacy RoW markets

Margin levers:
↑Mix shift to oncology and peptides — Unit 5 and Unit 6 carry 32–40% EBITDA margins versus 18–21% for legacy injectables; as their share grows, blended margin lifts to 28%
↑Operating leverage on a fixed cost base — 80+ scientists already funded; employee cost drops 9% → 7.2% of sales; every incremental ₹100 revenue delivers ₹32+ to EBITDA

The closing thought

KPL is not Venus Remedies — it does not own patent-protected molecules that competitors cannot legally copy. It is not Senores — it does not get 180-day exclusivity windows that generate one-time earnings spikes. What it has is more patient and more durable: 200+ process dossiers across 40 countries, each one running a multi-year supply contract that a distributor cannot exit without a 2–3 year regulatory penalty. Add a new country, add a new product, lock in another partner — repeat.

No arbitrage. No IP fortress. Just a quietly compounding technology transfer machine where the revenue engine runs on filings, not patents, and grows one locked-in distributor at a time.

The only real question is whether the factory passes its next EU-GMP audit — because that is the gate that lets the next wave of filings convert into revenue

[Not investment advice, DYOR]

[TruthCapital @ramesh_vd]

@arunattarde on the higher side!

[TruthCapital @ramesh_vd]

@wideclops @jaingourav31087 Yes

[TruthCapital @ramesh_vd]

#Merritronix #MerritronixLtd

Merritronix Ltd — a defence electronics IPO worth understanding. A thread.

What it does
Merritronix builds mission-critical electronics — radar sub-assemblies, avionics modules, flight control systems — for India's defence and aerospace programs. Not a generic PCB assembler. A certified, turnkey box-build manufacturer that HAL and BEL trust with the electronics inside fighter jets and radar networks. 97.8% of revenues come from Aerospace & Defence.

The moat
You can't just walk in. IPC Class 3 + EN 9100 certifications take years to earn. Vendor onboarding with defence PSUs runs 3–5 years. Once embedded, switching mid-program means full re-certification — so clients don't. 86% repeat customer rate proves it. The real edge isn't a patent. It's a compliance fortress that keeps competitors out and customers locked in.

Management
Founder-led. 35+ years in the industry. 60–64% promoter stake with zero shares pledged. They walked away from low-margin job-work, rebuilt around high-reliability turnkey systems, and now run EBITDA margins of 17%+ vs. the 5–8% typical for generic EMS. The ₹70 Cr IPO capital is being deployed into new SMT lines and cleanrooms — without touching debt. Skin firmly in the game.

Revenue drivers & operating leverage
Defence indigenisation ("Make in India") is a structural tailwind — HAL and BEL are mandated to source locally. Obsolescence engineering (reverse-engineering discontinued parts for ageing military fleets) is a high-margin niche with almost no competition. As revenues scale, fixed factory costs spread thinner. FY26 proved it: revenue +36.5%, net profit +85.9%. Operating leverage is real and kicking in.

EPS & growth prospects
EPS was ₹11.50 in FY26 (restated on post-IPO share base). FY27E: ₹15.19. FY28 range: ₹18 base case (70–75% utilisation, ₹250 Cr revenue) to ₹23.44 bull case (83%+ utilisation, ₹300 Cr). Post-IPO capacity ceiling rises to ₹325 Cr. The TAM for defence ESDM grows at ~18% CAGR to ₹28,000 Cr by 2030. Merritronix currently holds ~1% of it.

The one watch item
62% of revenues come from a single customer. That's the thread you pull if you want to worry. A procurement delay or budget freeze at that one client hits the top line directly. Working capital is also negative today — defence billing cycles are long. Both are manageable but they are real risks, not footnotes.

Closing
Merritronix is not a story about growth at any cost. It's a story about a niche manufacturer that spent 20 years earning the right to be in the room — and is now using public capital to scale what's already working. Narrow moat, widening. Grade A− management. A business that gets harder to compete with every year it stays compliant. Worth watching closely.

[Not investment advice, DYOR]

[TruthCapital @ramesh_vd]

#SenoresPharma #SENORES

A pharma company with 42% EPS CAGR trades at just 17.9× FY28E. Is the market pricing a two-year earnings spike about to peak — or completely missing what this business actually is? Here is the full picture on Senores Pharmaceuticals. 🧵

What it does

Most generic pharma companies make a drug and sell it once. Senores operates two distinct businesses out of the same factory — and that distinction is why the margins look nothing like a typical generics company.

Business 1 — Own ANDA portfolio. Senores spends 2–3 years earning USFDA approval for complex drugs — controlled substances, oncology injectables, high-barrier specialty molecules. It owns the approved dossier. It manufactures every unit at its own plants in India and Atlanta. But instead of building a US sales force, it licenses distribution rights to large partners like Dr. Reddy's. Dr. Reddy's pays Senores three times: an upfront licensing fee for the right to sell, a per-batch supply price for every unit manufactured, and a back-end profit share from US sales. Dr. Reddy's earns only from selling. Senores earns from all three — with none of the sales overhead.

Business 2 — CMO/CDMO manufacturing. Here a third party already owns the drug approval and simply pays Senores to manufacture it at their facility. Senores earns only the manufacturing margin — one revenue layer, not three. Lower margin than the ANDA business but steady, volume-driven, and it sweats the same factory assets that the ANDA business already paid for.

The combination drives 29–33% EBITDA margins — high-margin ANDA licensing stacked on top of a contract manufacturing base that keeps the plants fully utilised between own-product batches.

The moat

Not a patent. It is time, compliance, and geography — three things money alone cannot shortcut.

Each USFDA drug approval takes 2–3 years and is tied to a specific facility. Senores has 51 approved. A competitor starts from zero.

The DEA licence in Atlanta is rarer still. Manufacturing controlled substances on US soil requires high-security infrastructure and compliance audits most Indian pharma companies have never attempted. It opens direct US government supply contracts that are simply unavailable to everyone else.

For select approvals, the USFDA grants a 180-day exclusivity window — Senores is the only generic supplier before competitors can legally enter. 28 more filings in progress means this is a repeating cycle, not a one-time event.

Once Dr. Reddy's integrates a Senores-supplied product, switching requires finding another USFDA-cleared manufacturer for the same molecule, passing fresh facility audits, and running full-scale batches — all while risking US pharmacy stock-outs. Nobody does that over a price difference.

The FY28 numbers

FY26A: Sales ₹679 Cr · EBITDA ₹199 Cr (29.4%) · PAT ₹121 Cr · EPS ₹30.85 · ROIC 23.5%

FY28E: Sales ₹1,235 Cr · EBITDA ₹414 Cr (33.5%) · PAT ₹287 Cr · EPS ₹62.08 · ROIC 28.1%

Two structural drivers power this — operating leverage on a fully staffed cost base (every incremental ₹100 revenue drops ₹34 to EBITDA) and a 51-approval launch calendar already on paper. One transient item: IPO proceeds permanently wiped ₹23 Cr of finance costs — that step-change is now in the base and does not repeat. FY27 and FY28 need no new catalyst. At 17.9× FY28E the market is pricing a 42% EPS CAGR as if it flatlines the moment FY28 closes.

What could re-rate this significantly — and why

① 28 new filings confirm the launch engine keeps running.
The market's single biggest concern is that FY26–28 was a one-time wave of exclusivity windows rather than a sustainable machine. Confirmation that a fresh wave is incoming transforms the narrative from cyclical earnings spike to structural compounder with a rolling launch calendar.

② US government mandates onshore controlled-substance supply.
Government institutional contracts are annuity revenue — fixed volumes, predictable pricing, multi-year tenure, no sales effort required. This type of revenue is structurally different from product-by-product licensing deals and commands a higher earnings quality premium from the market

③ CDMO segment gets valued separately.
The contract manufacturing business is guided at ₹210–250 Cr in FY27 alone — already large enough to stand on its own.
- Because their revenue is contracted, visibility is high, and capital requirements are low.

④ Emerging markets inflects commercially.
Senores has 285 registered products and 636 under registration across Latin America, Africa, and Asia. - Currently sub-scale in revenue contribution.
Diversifying from US concentrated regulatory play.

The closing thought

Is the market pricing a two-year earnings spike that peaks at FY28 — or has it simply not looked closely enough at what a 28-molecule filing pipeline, a DEA licence nobody else in Indian pharma holds, and a CDMO base growing on the same assets can quietly compound into over the next five years? 🤔

[Not investment advice, DYOR]

[TruthCapital @ramesh_vd]

#venusremedies

Is Venus Remedies a boring 15–20% compounder quietly doing hospital supply rounds — or a deeply misunderstood asymmetric bet hiding behind a pharma label nobody bothers to read? 🧵

The business
Venus Remedies is not your typical pharma company grinding out generic tablets for retail chemists. It operates in a niche that most investors walk past: sterile injectable formulations for hospital ICUs — antibiotics that fight drug-resistant superbugs, chemotherapy injectables, and critical care drugs that can only be delivered intravenously in a controlled clinical setting.

For nearly a decade the company struggled — good science, poor commercialisation, heavy debt. Then management made two pivots that changed everything: they stopped selling complex molecules directly, instead signing manufacturing alliances with Cipla, Zydus, and Intas who already owned hospital relationships. And they cleared every rupee of debt from operating cash flow. Today Venus runs a debt-free balance sheet with ₹250+ Cr in unencumbered cash — while its sterile lines run at near-full capacity.

The moat — especially the IP layer
Two-layer moat.
The outer wall: 1,000+ global Marketing Authorisations(license to sell medicines) tied to specific plants, non-transferable, each taking 18–36 months to secure. Any competitor replicating Venus's export footprint needs a decade and hundreds of crores just for paperwork.

The inner wall — the one the market keeps mispricing — lives inside the Venus Medicine Research Centre (VMRC). A DSIR-recognised in-house lab generating 135+ global patents across the US, EU, and India. The core breakthrough: proprietary Antibiotic Adjuvant Entities — molecules that don't just treat infections, they disarm the bacterial resistance mechanism itself. The flagship Elores shields antibiotics from the beta-lactamase and carbapenemase enzymes bacteria use to neutralise them.

Management — why trust them

Two reasons: tested under pressure, and kept their word.

Dr Manu Chaudhary (Joint MD, PhD structural biology) personally anchors the 135+ patent portfolio — a promoter-scientist who built the core moat. Pawan Chaudhary (MD) architected the commercial pivot. Saransh Chaudhary (next-gen, CEO Venusiac) now drives global out-licensing of Elores.

Promoters hold 41.76% equity with zero shares pledged. When debt was heavy and commercialisation was stalling, management did not dilute equity, did not diversify — they paid down every rupee from operations. FY26 net profit: ₹102.78 Cr, up 127% YoY. Under-promise, over-deliver.

Current numbers and EPS trajectory
FY26 actuals: Sales ₹769.6 Cr · EBITDA margin 18.5% · PAT ₹102.8 Cr · EPS ₹76.9 · ROIC 21.8% · CFO ₹155 Cr — cash conversion 1.5× reported profit.

Base-case model at 15–18% guided revenue growth: FY27E EPS ₹91.7 · FY28E EPS ₹128.7. At CMP ₹1,610, that is 12.5× forward P/E on FY28E — priced as if it is still the debt-heavy generic manufacturer of five years ago.

The asymmetric bet — four levers and why now

Most estimates only capture revenue growth. The real asymmetry is what happens when product mix shifts toward high-margin, IP-protected molecules.

1. Mix shift: generic → proprietary IP drugs — the highest-probability lever and the most direct EPS driver. Venus sells a blend of commodity generics (gross margin ~28–30%) and proprietary patented formulations like Elores (gross margin ~45–50%+). As Elores scales deeper into hospital formularies, every 5% revenue mix shift adds ~150–200 bps EBITDA margin. On just 1.33 Cr shares, each 100 bps margin expansion = ~₹5–6 EPS uplift. If EBITDA exits at 26–28% instead of 22.5%, FY28E EPS reaches ₹155–170 — not ₹128.

2. Global Elores out-licensing milestones — Venus already received a ₹11 Cr milestone payment from one AMR licensing deal. Each EU or US agreement adds upfront fees plus multi-year royalties — zero incremental capex. Two or three deals could add ₹15–25 Cr PAT annually, translating to +₹11–19 EPS purely from licensing income.

3. AMR becomes a global policy emergency — WHO, G7, and EU have flagged antimicrobial resistance as a tier-1 crisis. Fast-track procurement frameworks for proven AMR therapies are being legislated now. Venus is one of the very few companies globally with commercially validated, patented, adjuvant-based AMR solutions already in 60+ countries — a potential strategic acquisition target for Big Pharma missing this platform entirely.

4. Plerixafor oncology inflection — entry into the $65B → $105B chemo injectable market via GCC and EU hospital formularies. EU-GMP manufacturing and regulatory filings are already in place. Adoption is a matter of when, not whether.

⚡ Why now — five reasons the window is open today
→ Balance sheet inflection just happened. The debt paydown that unlocks all future optionality was completed in FY26. You are evaluating this in the first year of a clean, self-funding capital structure

→ Capacity expansion is being commissioned now. The ₹65 Cr Baddi lyophilisation line — which raises the revenue ceiling from ₹850 Cr to ₹1,150 Cr — goes live in Q2 FY27. The earnings impact will show up in the next 2–3 quarters.

→ Mix shift is at its earliest visible stage. EBITDA expanded from 12% to 18.5% in a single year as patented molecules grew faster than generics. The inflection has started . At 22–28% EBITDA, this is a completely different earnings machine.

→ Global AMR policy is accelerating. The EU's AMR Action Plan and the US PASTEUR Act are moving from discussion to legislation in 2025–26. Governments are creating guaranteed procurement frameworks for validated AMR drugs — and Elores is one of the very few that qualifies today.

→ Valuation has not caught up (or has it ??). At 12.5× FY28E on a debt-free, 21%+ ROIC, IP-protected business with an expanding moat — the stock is priced for a generic compounder's destiny, not a specialty pharma platform's (it may be totally wrong to interpret this way).

Venus Remedies is an IP-protected, debt-free, founder-scientist-run specialty pharma company at 12.5× FY28E earnings. The base case already works. The mix-shift toward proprietary molecules is already happening and unpriced. The licensing optionality, AMR tailwind, and oncology expansion sit on top as free options. The window is open because the balance sheet cleared last year and the capacity expansion fires next quarter.

Is the market still seeing a debt-laden generic injectable manufacturer from five years ago — or has it simply not looked closely enough at what is quietly being built inside?

[Not investment advice, DYOR]

[TruthCapital @ramesh_vd]

@rachit11995 Its a research put together fr9m multiple sources

[TruthCapital @ramesh_vd]

#sedemac #sedemacmechatronics

An IIT Bombay lab project is now the invisible brain inside millions of India's scooters, EVs & diesel generators — and nobody is talking about it. Here's the full picture on Sedemac Mechatronics 🧵

The setup
Born from a question — why are Indian OEMs buying over-engineered Bosch ECUs for engines that run in completely different conditions? Sedemac was built to answer that. Not as a component maker, but as a software-IP firm that ships its code embedded inside hardware. Their sensorless control algorithms eliminated the starter motor, sensor hub, and wiring loom from two-wheelers entirely — one smart ECU does it all.

Two bets. Both winning.
EV power electronics — every electric scooter and e-rickshaw needs a motor controller. Sedemac ported its sensorless motor expertise into EV inverters. TAM grows from ₹3,100 Cr → ₹11,400 Cr by 2030 at 31% CAGR. Current share ~3.5%, targeting 20%. Industrial genset electronics — digital governors and AVRs for hospitals, telecom towers, data centres. 75%+ domestic market share already. Now expanding into US and European off-highway equipment.

The moat is genuinely wide
ECUs are designed-in at the vehicle blueprint stage — switching mid-lifecycle costs an OEM ₹15–30 Cr and 18 months of delays. ARAI certifications are non-transferable, platform-specific, and take 12–18 months to earn. Sensorless ISG + EFI patents run into the 2030s. Platform retention >90%. LTSAs lock volumes for 5–7 years per model cycle. ROIC spread of >3,000 bps over WACC. Competitive Advantage Period rated 10+ years.

Capacity & capex
Current plants (Chakan + Dhayari) — 5.7 Mn units/yr, revenue ceiling ₹1,100 Cr. Bhosari SMT complex comes online FY27 — adds 4.65 Mn units/yr, unlocking another ₹900 Cr. Combined ceiling: ₹2,000 Cr. Funded entirely from internal cash — FY26 FCF was ₹185 Cr on capex of just ~₹40 Cr. Zero balance sheet stress.

Margin levers
Gross margins 38–40% vs peers at 22–28% — the gap is code, not components. Employee costs fall from 9.3% → 7.5% of sales as volumes scale over a fixed R&D base. Finance cost collapses from ₹12 Cr → ₹3.8 Cr. Net debt-free. Interest cover heading to 35×. Result: EBITDA 18.4% → 22.7%, PAT 7.1% → 13.6%, ROIC 24.5% → 43.2% — all in four years.

The numbers
FY26A: Sales ₹1,058 Cr (+61% YoY) · EBITDA ₹217 Cr · PAT ₹104 Cr · EPS ₹23.7 · CFO ₹172 Cr.
Management guided >30% revenue growth for next two years. At 30% CAGR:
FY27E → ₹1,375 Cr sales · EPS ₹37.7  |  FY28E → ₹1,788 Cr · EPS ₹54.8 · CFO ₹312 Cr.

Valuation
At CMP ~₹2,587, trailing P/E is 109× — yes, expensive. But on FY28E at 30% CAGR, that compresses to ~47×. For a business with a 10+ year moat, 43% ROIC, widening competitive position, and management guiding >30% growth — 47× is the market pricing in flawless execution, not speculation. The Bhosari ramp and EV mix crossing 12% of revenue are the catalysts. Watch Q2 FY27.

Risks
Customer concentration — one large OEM carries outsized revenue weight. Any platform discontinuation is a cliff risk. Chinese entrants — BYD/Inovance tier-2 suppliers with subsidised hardware could target Indian 2W/3W price points. ARAI certifications buy time, not permanent protection.

Verdict
India's most uniquely protected play on EV electrification + industrial power digitisation, built on an IIT-born patent moat, funded by its own cash flows, run by founders with skin in the game. The moat is real. The valuation demands execution. The numbers say it can deliver.

[Not investment advice, DYOR]

[TruthCapital @ramesh_vd]

@jaingourav31087 Approx. FY27 and FY28 estimates are in the image.

[TruthCapital @ramesh_vd]

@GingerInvest44 planning to !

[TruthCapital @ramesh_vd]

#shreerefrigerations #aeroflex #KRNheatexchanger

The Indian DC Cooling Supercycle: 3 Stocks, 3 Strategies — Pick Your Risk/Reward

India's AI infrastructure buildout is creating a thermal management supercycle. Three companies are positioned to capture it — but they play completely different games. Know which one fits your portfolio. 🧵

1/ Shree Refrigerations — Deep Value hiding behind a Defense Moat
Most are chasing Aeroflex. The real alpha is hiding in plain sight.
Modality: Central bulk water-chilling engines — the baseline cooling every data center needs. Cloud AND AI. Generic solution = wider TAM than any niche play.
Defense is the backstop: Only Indian vendor certified for all 3 naval cooling sub-systems. 3-5 year shipyard validation. ~80% naval HVAC market share. Unreplicable.
DC is the upside: Smardt MagLev oil-free tech cuts PUE by 20-50%. 70,000 sq ft Karad plant moves to localised manufacturing post-FY28. Trezor subsidiary stacking sticky multi-year AMC contracts quietly.
Numbers: ₹154 Cr → ₹1,000 Cr by FY31 (45%+ CAGR). PEG 0.34. ROIC 22-25% vs 12% WACC.
✅ Defense monopoly as permanent backstop | Cloud + AI TAM = largest of the three | AMC recurring revenue compounding | Q4 FY26 net margin hit 19.3% on operating leverage
⚠️ Doesn't own Smardt IP — exclusivity risk | ~370 day cash cycle | DC revenues back-loaded to FY28
Verdict: Defense moat + oil-free tech + AMC stickiness + 0.34 PEG. DC exposure with structural armor underneath.

2/ Aeroflex — Pure-Play AI Infrastructure with Owned Technology
Modality: Liquid Cooling Skids and Secondary Fluid Networks routing coolant directly to GPU chips at >500W. Air cooling fails here. Liquid is the only answer.
IP is 100% owned. No licensing. No royalty drag. 30 years of proprietary SS corrugation process trade secrets.
Switching cost is existential — one coolant leak destroys millions in active GPU arrays. Clients cannot afford to switch.
Capacity: 2,000 → 15,000 skids/year. Frame deal with $50B+ US tech corp signed. TAM: $3B → $21B by 2030 at 33% CAGR.
Numbers: 63% EPS CAGR to FY28. EBITDA targeting 24.5%. Debt-free. 60-day debtor cycle. FY28 P/E at 36.63x.
✅ 100% owned IP — zero partner risk | Near-infinite switching costs near GPU arrays | Only Indian hyperscaler-certified SS liquid cooling skid maker | Cleanest balance sheet of the three
⚠️ 60% international revenues = tariff exposure | Pure AI CapEx play — order pipeline mirrors hyperscaler spend | 36.63x FY28 P/E leaves zero execution room
Verdict: Owned IP. Existential switching costs. $21B TAM. 63% EPS CAGR. Purest AI infra play in India.

3/ KRN Heat Exchangers — The Volume Machine Riding the OEM Wave
Modality: Fin & tube coils built to OEM print. Daikin designs the chiller — KRN stamps the coil inside it. Industrially. At scale.
No proprietary tech needed. No direct hyperscaler relationship needed. DC buildout fills OEM books — KRN rides the wave automatically.
Scale is the story: ₹1,000 Cr Rajasthan facility targeting 50% of Indian hyperscale DC coil demand. 6x capacity. Only 20% utilized today — operating leverage ahead is enormous. Fully backward integrated. Cost pass-through shields margins.
Numbers: ₹430 Cr → ₹1,350 Cr by FY28. 69% EPS CAGR. PEG 0.50. 17% concessional tax rate.
✅ 69% EPS CAGR at 0.50 PEG — cheapest earnings growth of the three | 6x plant at 20% utilization = massive leverage ahead | China-plus-one pulling OEM sourcing to India
⚠️ Daikin = 33% of revenue — one relationship defines the thesis | Narrow moat — replicable with capital | Builds to client print — EBITDA structurally capped ~19.5% | OCF negative during growth phase
Verdict: Not a moat buy. A capacity cycle buy. Maximum operating leverage at the lowest valuation.

[Not investment advice, DYOR]

[TruthCapital @ramesh_vd]

@JatinKh40378056 Thanks. There is no fixed prompt. I kept changing it based on what I wanted in the table.

[TruthCapital @ramesh_vd]

#RIRpower #RIRPowerelectronics
RIR Power Electronics — whether the market is pricing a dream or a reality?

What the bet actually is
In Odisha, RIR is building a ₹618 crore Silicon Carbide semiconductor fab. Today they assemble imported parts and earn ~12% EBITDA margins. When that plant runs, they make the chips themselves — for EVs, AI data centres, solar — at margins that could hit 23-27%. That's the entire story. Everything else is context.

Three triggers, in order
July 2026 — Plant commissioning. Management confirmed commissioning by July end. First commercial SiC shipment is your proof-of-concept signal. Miss this date and the thesis slips a year. Screener
FY28 — Margin inflection. At 70% utilisation, EBITDA doubles. PAT goes from ₹8 crore to ~₹25 crore. At current price that's still 52x forward earnings — rich, but no longer absurd.
FY28-29 — International scale. First overseas order already secured. If RIR becomes a cost-competitive SiC exporter, the revenue ceiling breaks open entirely.

Why trust management
Promoters hold ~71%, zero pledged. Twenty-year turnaround track record. Clean books. Every Odisha milestone hit so far. For a small-cap, that's rare.

The honest catch
No margin of safety exists at this price. FCF is deeply negative. The company needs subsidies, debt, and possibly dilution to get through FY27. And if global SiC supply floods by 2028, the margin expansion story softens.

Bottom line
Real growth arrives in FY28 — not before. Until then this is a milestone trade, not a fundamentals trade. Watch the Odisha commissioning this July. That single event either validates the next three years or delays them.

[Not investment Advice, DYOR]

[TruthCapital @ramesh_vd]

#ConcordControl

Concord Control Systems — Why This Railway Tech Play Stands Out
Revenue engines:
· ₹697 Cr order book (3.3× revenue)
· Kavach 4.0 rollout
· Vande Bharat electronics
· capacity ceiling doubling to ₹590 Cr post ARC + Fusion integration

Margin story:
· EBITDA 23% → 33% by FY28
· product mix shifting from fans/lights to safety-critical software systems
· employee costs compressing as Lucknow hub scales
· COGS declining as embedded SW share rises

Moat: Narrow moat, widening.
· RDSO approval = 3–5 yr non-replicable barrier
· mid-lifecycle switching voids safety warranties
· asset-light 28% EBITDA at scale
· only Indian EMS vendor blending certified hardware with Kavach 4.0 embedded SW

Management:
· ₹49 Cr → ₹210 Cr revenue in 3 yrs
· beat every margin guidance
· 65.57% promoter stake, 0% pledged
· promoter salary capped at ₹1.8 Cr
· ARC + Fusion M&A executed cleanly

EPS compounding — the punchline:FY25: ₹22 → FY26: ₹42 → FY27E: ₹75 → FY28E: ₹112 That's a 5× in 3 years · 71% CAGR · earnings growing faster than revenue as operating leverage kicks in

[Not investment advice. DYOR]

[TruthCapital @ramesh_vd]

#AEROFLEX #AEROFLEXINDUSTRIES

Aeroflex Industries is the quiet infrastructure play behind the AI boom. A thread 🧵

Revenue Drivers :
Revenue engine firing on all cylinders:
→ AI cooling skids scaling 2,000 → 15,000 units/yr
→ Hose capacity expanded to 17.5M metres (Jan '26) |
→ TAM: Liquid cooling alone hits ₹1,75,000 Cr by 2030 (33% CAGR)
→ Rolling order book: ₹145 Cr; repeat wins from a $50B+ US tech co.
→ Aero & defence niche: ₹8,500 Cr TAM, ISRO + rocket test beds
→ Hyd-Air (Pune) opens railways + hydraulic fittings vertical
→ China+1 sourcing shift actively pulling Western OEM orders
→ Mgmt guidance: 25%+ EBITDA compounding target

Margin Levers:
Margins structurally expanding — not cyclical luck:
→ EBITDA: 21% → 26.5% by FY28E
→ Product mix shift: high-value skids & aero moving to 70% of revenue
→ Metal cost pass-through clauses — Ni/Cr price swings go straight to customers, GM stays protected
→ Automation: staff cost falling from 9.35%
→ 8.5% of sales → Zero LT debt: finance cost <₹1 Cr, interest cover 100×+
→ PAT margin: 12.6% → 17.3% by FY28E

Moat:
Why this is hard to replicate:
→ EN ISO 10380 + UL + CE + ABS certifications across 80+ countries — take 24–36 months to get, tied to the Taloja plant, non-transferable
→ Customer retention >85–90%; switching costs = 12–18 month re-qualification
→ Process trade secrets in corrugation speed, metallurgy & micro-welding — no patents needed
→ JNPT port proximity = structural logistics edge on 80%+ export volumes
→ ROIC 22% → 32% by FY28E vs. WACC ~11.5% — wide spread, widening
Verdict: Wide Moat. CAP 10+ years.

Management:
Management you can trust:
→ Promoter stake: 66.98%, zero shares pledged
→ Said they'd go debt-free post-IPO. Did it.
→ Said they'd scale to 15K cooling skids/yr. Doing it.
→ ₹55 Cr QIP deployed (Feb '26) for capacity without diluting control
→ Clean SEBI record, no audit qualifications, arm's-length RPTs

Numbers:
→ EPS ₹4.28 → ₹11.38 (63% CAGR) · ROIC crossing 32% by FY28E — all self-funded, zero debt.

Risks to watch:
→ Raw material: Stainless steel/nickel spike beyond pass-through buffer
→ Execution: Scaling technical workforce fast enough before hyperscalers lock in rivals
→ Concentration: ~82% export mix — any US/EU tariff shock hits hard
→ Tech shift: If server architecture moves away from liquid cooling skids, factory re-tooling is expensive
→ China threat: State-backed Chinese hose makers with subsidised capex targeting Western routes

[Not an investment advice, DYOR]